Short answer
Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results for quarter ended March 31, 2026.
Evolus, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release issued May 4, 2026
- Detailed results available in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Evolus terminated its $50.0 million at-the-market equity offering agreement on May 1, 2026
- No shares were sold under the facility, avoiding dilution from this program
- Termination removes a potential equity funding source and may constrain future financing flexibility
- Disclosure indicates no proceeds were raised through the terminated sales agreement
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $73.1M, up 7%, with toxin revenue $66.4M and HA gel revenue $6.7M
- Adjusted EBITDA $0.6M versus $(5.5)M, marking a second consecutive positive quarter and 0.8% margin
- GAAP operating loss narrowed to $6.8M from $15.2M, while GAAP net loss remained $(10.7)M
- 2026 outlook reaffirmed: revenue $327M-$337M, non-GAAP expenses $210M-$216M, low- to mid-single-digit EBITDA margin
- Cash $49.8M versus $53.8M, with approximately $120M additional capacity supporting launches and tariff mitigation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolus, Inc. 8-K filings
Get the next EOLS 8-K as it lands
Follow EOLS for push alerts, or ask the research agent what this filing means.